Monitoring Tumor Markers in Testicular Cancer Patients
Author Information
Author(s): B.M. Colls
Primary Institution: Oncology Service, Christchurch Hospital
Hypothesis
Patients with non-seminomatous germ cell tumors should have their tumor markers evaluated weekly instead of monthly during the first 6 months.
Conclusion
The experience from New Zealand suggests that more frequent monitoring of tumor markers may not be necessary as relapses did not occur at concerning marker levels.
Supporting Evidence
- 36 out of 115 patients relapsed during the study.
- 29 patients relapsed within the first year, with 21 relapsing in the first 6 months.
- The highest beta HCG level at relapse was 150 IU.
- The highest alpha fetoprotein level recorded was 170 g.
Takeaway
Doctors in New Zealand found that checking tumor markers more often didn't help them catch relapses in testicular cancer patients.
Methodology
Data was collated from five centers over 10 years, with monthly assessments in the first year and less frequent assessments in subsequent years.
Limitations
The study is based on a small sample size and may not represent all patients.
Participant Demographics
Patients with non-seminomatous germ cell tumors from five New Zealand oncology centers.
Want to read the original?
Access the complete publication on the publisher's website